Biolojic Design inks multi-target drug collaboration with Merck

Israel-based artificial intelligence (AI) focused biotech Biolojic Design has entered into a multi-target drug discovery collaboration with Germany’s Merck KGaA (MRK: DE).

The partnership will leverage Biolojic Design’s AI-driven discovery platform to design therapeutic antibodies for the treatment of cancer and immunological disorders.

“We’re excited to work with Merck KGaA, Darmstadt, Germany, to generate best-in-class  treatments for patients with cancer and immunological disorders,” said Yanay Ofran, chief executive and founder of Biolojic Design. "Biolojic’s clinically validated AI platform allows us to modulate human biology in a uniquely precise way to treat disease, giving us the potential to discover medicines against well validated targets. In this collaboration, we will apply our multibody capabilities to create next generation antibody-based therapies, including ADCs with the potential to block tumor escape mechanisms, overcome tumor and patient heterogeneity and offer improved safety and efficacy,” he added.